Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05270863 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia
A Phase 3 study, sponsored by Visus Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 182
- Enrollment target
NCT05270863: Completed Phase 3 study, sponsored by Visus Therapeutics.
NCT05270863 is a Phase 3 study that has completed, run by Visus Therapeutics. The registered enrollment target is 182 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05270863, a Phase 3 study, has completed, sponsored by Visus Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 182 participants
- Enrollment target
Study Summary
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Primary Outcome
Primary endpoint measure at hour 1 post-dose at study visit
Interventions
- DRUG BRIMOCHOL™ PF
- DRUG Carbachol PF
- DRUG Brimonidine tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2022-03-30 |
| Est. Completion | 2023-04-10 |
| Phase | Phase 3 |
What the finished NCT05270863 record still lists
NCT05270863 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 3 interventions - of which BRIMOCHOL™ PF is the first listed.
NCT05270863 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05270863 about?
NCT05270863 is a clinical study titled "Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia". Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
What is the current status of trial NCT05270863?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 182 participants. The study started on 2022-03-30. Estimated completion is 2023-04-10.
What interventions are being tested in trial NCT05270863?
The interventions under investigation include: BRIMOCHOL™ PF (DRUG), Carbachol PF (DRUG), Brimonidine tartrate (DRUG).
Who is sponsoring clinical trial NCT05270863?
This trial is sponsored by Visus Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05270863's enrollment target sits among peer trials
182 1421st of 2000 higher than 579 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- NCT04323735 · 182 participants · Phase 2
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
- NCT05606731 · 182 participants · NA
Family Intervention to Prevent Childhood Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI